Trial · NCT07890480
Aztreonam-Avibactam in Immunocompromised Hosts
NCT07890480, Recruiting, Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Aztreonam-Avibactam in Immunocompromised Hosts. Trials, record NCT07890480. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07890480
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Aztreonam-Avibactam in Immunocompromised Hosts
- NCT number
- NCT07890480
- Status
- Recruiting
- Enrollment
- 814 participants, estimated
- Lead sponsor
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
- Conditions
- Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection, Immunocompromised Host, Drug Resistance, Multiple, Bacterial
- Interventions
- Aztreonam-Avibactam, Ceftazidime-Avibactam Plus Aztreonam
- First posted
- 2026-10-22
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | All-Cause Mortality at Day 30 | Within 30 days after treatment initiation | Proportion of participants who die from any cause within 30 days after initiation of aztreonam-avibactam (ATM-AVI) or ceftazidime-avibactam plus aztreonam (CZA-ATM), regardless of the cause of death. |
| Secondary | Favorable Clinical Response at Day 7 | Day 7 after treatment initiation | Proportion of participants with a favorable clinical response, defined as the absence of fever and hypotension, together with improvement in the signs and symptoms of the index infection. |
| Secondary | Clinical Cure at the End of Treatment | At completion of antimicrobial treatment for the index infection | Proportion of participants achieving clinical cure, defined as resolution of fever and hypotension for at least 72 hours, together with resolution of the signs and symptoms of the index infection. The end of treatment corresponds to completion of all antimicrobial treatment directed at the infectious episode. |
| Secondary | Microbiological Cure | From treatment initiation through the end of treatment | Proportion of evaluable participants with documented conversion of cultures from the index infection site to negative. Assessment will be based on follow-up cultures obtained as part of routine clinical care. |
| Secondary | All-Cause Mortality at Day 7 | Within 7 days after treatment initiation | Proportion of participants who die from any cause within 7 days after initiation of ATM-AVI or CZA-ATM treatment. |
| Secondary | Infection-Related Mortality at Day 7 | Within 7 days after treatment initiation | Proportion of participants who die within 7 days after treatment initiation in the presence of microbiological, histological, or clinical evidence of active infection, after excluding alternative causes of death. |
| Secondary | Infection-Related Mortality at Day 30 | Within 30 days after treatment initiation | Proportion of participants who die within 30 days after treatment initiation in the presence of microbiological, histological, or clinical evidence of active infection, after excluding alternative causes of death. |
| Secondary | Infection Relapse Within 60 Days | Within 60 days after treatment initiation | Proportion of participants experiencing recurrence of infection caused by the same microorganism responsible for the index infection within 60 days after initiation of ATM-AVI or CZA-ATM treatment. |
| Secondary | Incidence of Hematological Abnormalities | During treatment and up to 30 days after treatment completion | Proportion of participants developing hematological abnormalities, including leukopenia (leukocyte count below 4,000/mm³), neutropenia (neutrophil count below 1,000/mm³), eosinophilia (eosinophil count above 500/mm³), thrombocytopenia (platelet count below 150,000/mm³), or anemia according to institutional reference ranges. |
| Secondary | Incidence of Hepatic Toxicity | During treatment and up to 30 days after treatment completion | Proportion of participants developing hepatic toxicity, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the upper limit of normal (ULN). Hepatitis is defined as transaminase elevation at least 5 times the ULN, or at least 3 times the ULN accompanied by symptoms such as abdominal pain, nausea, or vomiting. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07890480
GET https://conductscience.org/api/trials/v1/NCT07890480/registered